JP2008509912A - 医薬品としての複素環化合物 - Google Patents
医薬品としての複素環化合物 Download PDFInfo
- Publication number
- JP2008509912A JP2008509912A JP2007525749A JP2007525749A JP2008509912A JP 2008509912 A JP2008509912 A JP 2008509912A JP 2007525749 A JP2007525749 A JP 2007525749A JP 2007525749 A JP2007525749 A JP 2007525749A JP 2008509912 A JP2008509912 A JP 2008509912A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- substituted
- heterocyclyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title description 4
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 118
- 102000004311 liver X receptors Human genes 0.000 claims abstract description 75
- 108090000865 liver X receptors Proteins 0.000 claims abstract description 75
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 69
- 102100038495 Bile acid receptor Human genes 0.000 claims abstract description 39
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims abstract description 37
- 230000000694 effects Effects 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 35
- 208000035475 disorder Diseases 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 239000000556 agonist Substances 0.000 claims abstract description 17
- 208000024891 symptom Diseases 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 939
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 361
- 125000001072 heteroaryl group Chemical group 0.000 claims description 265
- 125000000623 heterocyclic group Chemical group 0.000 claims description 264
- 125000001424 substituent group Chemical group 0.000 claims description 242
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 230
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 226
- 125000005843 halogen group Chemical group 0.000 claims description 223
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 212
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 211
- 125000000217 alkyl group Chemical group 0.000 claims description 185
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 184
- 125000003118 aryl group Chemical group 0.000 claims description 176
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 174
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 160
- 125000001188 haloalkyl group Chemical group 0.000 claims description 148
- 125000002577 pseudohalo group Chemical group 0.000 claims description 142
- 229910052739 hydrogen Inorganic materials 0.000 claims description 94
- 239000001257 hydrogen Substances 0.000 claims description 94
- 125000003107 substituted aryl group Chemical group 0.000 claims description 84
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 82
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 68
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 64
- 125000000304 alkynyl group Chemical group 0.000 claims description 63
- 125000003342 alkenyl group Chemical group 0.000 claims description 61
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 56
- 229910052717 sulfur Inorganic materials 0.000 claims description 52
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims description 49
- -1 —R 9 —C (J) R 13 Chemical group 0.000 claims description 48
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 47
- 150000002431 hydrogen Chemical class 0.000 claims description 47
- 108020004017 nuclear receptors Proteins 0.000 claims description 46
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 38
- 229910052760 oxygen Inorganic materials 0.000 claims description 37
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 29
- 125000002947 alkylene group Chemical group 0.000 claims description 21
- 229940107161 cholesterol Drugs 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
- 201000001320 Atherosclerosis Diseases 0.000 claims description 14
- 239000005557 antagonist Substances 0.000 claims description 12
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims description 12
- 239000003613 bile acid Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 239000012190 activator Substances 0.000 claims description 10
- 230000004060 metabolic process Effects 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 7
- 206010008635 Cholestasis Diseases 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 6
- 230000007870 cholestasis Effects 0.000 claims description 6
- 231100000359 cholestasis Toxicity 0.000 claims description 6
- 201000001421 hyperglycemia Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 208000006132 lipodystrophy Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- GCVLCLFIEOVLMG-UHFFFAOYSA-N 2-(3-acetylphenyl)imino-5-(2,3-dihydroindol-1-ylmethylidene)-3-(furan-2-ylmethyl)-1,3-thiazolidin-4-one Chemical compound CC(=O)C1=CC=CC(N=C2N(C(=O)C(=CN3C4=CC=CC=C4CC3)S2)CC=2OC=CC=2)=C1 GCVLCLFIEOVLMG-UHFFFAOYSA-N 0.000 claims description 2
- UEKDOPPDCYNGHM-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3,5-dibenzyl-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(CC=2C=CC=CC=2)S1 UEKDOPPDCYNGHM-UHFFFAOYSA-N 0.000 claims description 2
- HLSDYWFUKOZJTE-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-(2,3-dihydroindol-1-ylmethylidene)-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN1C2=CC=CC=C2CC1 HLSDYWFUKOZJTE-UHFFFAOYSA-N 0.000 claims description 2
- UYOKDJNIHORDNT-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-(2-phenylethyl)-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(CCC=2C=CC=CC=2)S1 UYOKDJNIHORDNT-UHFFFAOYSA-N 0.000 claims description 2
- QRMFPGOYLMAMMW-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-(dimethylaminomethylidene)-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(=CN(C)C)S1 QRMFPGOYLMAMMW-UHFFFAOYSA-N 0.000 claims description 2
- PZCIROBDGVLEIL-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-(furan-2-ylmethylidene)-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CC1=CC=CO1 PZCIROBDGVLEIL-UHFFFAOYSA-N 0.000 claims description 2
- PDXNFKUZVGOMRC-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[(3-methoxy-n-methylanilino)methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=CC(OC)=C1 PDXNFKUZVGOMRC-UHFFFAOYSA-N 0.000 claims description 2
- OMZSQHXDIDHBFC-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[(4-methoxy-n-methylanilino)methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=C(OC)C=C1 OMZSQHXDIDHBFC-UHFFFAOYSA-N 0.000 claims description 2
- ZWQHCOQRXKFJGB-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[(4-methylpiperazin-1-yl)methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN1CCN(C)CC1 ZWQHCOQRXKFJGB-UHFFFAOYSA-N 0.000 claims description 2
- VZGIJCXVUUINRV-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[(n-methylanilino)methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=CC=C1 VZGIJCXVUUINRV-UHFFFAOYSA-N 0.000 claims description 2
- KNPWYRGLLCQAQC-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[[3-(dimethylamino)propyl-methylamino]methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(=CN(C)CCCN(C)C)S1 KNPWYRGLLCQAQC-UHFFFAOYSA-N 0.000 claims description 2
- XABCMNNTHFJDCF-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[[4-(2-methoxyethoxy)-n-methylanilino]methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=C(OCCOC)C=C1 XABCMNNTHFJDCF-UHFFFAOYSA-N 0.000 claims description 2
- BZXKLXUWHZDDTA-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[[benzyl(methyl)amino]methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)CC1=CC=CC=C1 BZXKLXUWHZDDTA-UHFFFAOYSA-N 0.000 claims description 2
- GMUCPXKPCHHGMW-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-[[methyl(2-phenylethyl)amino]methylidene]-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)CCC1=CC=CC=C1 GMUCPXKPCHHGMW-UHFFFAOYSA-N 0.000 claims description 2
- KYXHFHACYVKHAB-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-benzylidene-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CC1=CC=CC=C1 KYXHFHACYVKHAB-UHFFFAOYSA-N 0.000 claims description 2
- FTTCNMOCBHYESC-UHFFFAOYSA-N 2-[5-acetyl-2-(ethylamino)phenyl]imino-3-benzyl-5-phenacyl-1,3-thiazolidin-4-one Chemical compound CCNC1=CC=C(C(C)=O)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(CC(=O)C=2C=CC=CC=2)S1 FTTCNMOCBHYESC-UHFFFAOYSA-N 0.000 claims description 2
- HKFQHSDEEUNRTI-UHFFFAOYSA-N 3-[[3-benzyl-5-(2,3-dihydroindol-1-ylmethylidene)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN1C2=CC=CC=C2CC1 HKFQHSDEEUNRTI-UHFFFAOYSA-N 0.000 claims description 2
- ZQWBBJKQQQLRBO-UHFFFAOYSA-N 3-[[3-benzyl-5-(dimethylaminomethylidene)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C1N(CC=2C=CC=CC=2)C(=O)C(=CN(C)C)S1 ZQWBBJKQQQLRBO-UHFFFAOYSA-N 0.000 claims description 2
- VOGNACRDQCXWGA-UHFFFAOYSA-N 3-[[3-benzyl-5-[(2-methoxy-n-methylanilino)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=CC=C1OC VOGNACRDQCXWGA-UHFFFAOYSA-N 0.000 claims description 2
- FRRBVAOXYDQYKI-UHFFFAOYSA-N 3-[[3-benzyl-5-[(4-methoxyanilino)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CNC1=CC=C(OC)C=C1 FRRBVAOXYDQYKI-UHFFFAOYSA-N 0.000 claims description 2
- MHGFLCUKXSCYJV-UHFFFAOYSA-N 3-[[3-benzyl-5-[(n-methylanilino)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=CC=C1 MHGFLCUKXSCYJV-UHFFFAOYSA-N 0.000 claims description 2
- DXNSGASFGISSOY-UHFFFAOYSA-N 3-[[3-benzyl-5-[[benzyl(methyl)amino]methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)CC1=CC=CC=C1 DXNSGASFGISSOY-UHFFFAOYSA-N 0.000 claims description 2
- NQQMUAALTMRXKD-UHFFFAOYSA-N n-[4-[[5-(2,3-dihydroindol-1-ylmethylidene)-3-(furan-2-ylmethyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1N=C(S1)N(CC=2OC=CC=2)C(=O)C1=CN1C2=CC=CC=C2CC1 NQQMUAALTMRXKD-UHFFFAOYSA-N 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000004031 partial agonist Substances 0.000 claims 10
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 6
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 6
- 239000013543 active substance Substances 0.000 claims 5
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 4
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 239000002876 beta blocker Substances 0.000 claims 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims 3
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims 3
- ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 3
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 3
- 229940123208 Biguanide Drugs 0.000 claims 3
- 102000013585 Bombesin Human genes 0.000 claims 3
- 108010051479 Bombesin Proteins 0.000 claims 3
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 claims 3
- 102000019432 Galanin Human genes 0.000 claims 3
- 101800002068 Galanin Proteins 0.000 claims 3
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 3
- 229940115480 Histamine H3 receptor antagonist Drugs 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 102000000853 LDL receptors Human genes 0.000 claims 3
- 108010001831 LDL receptors Proteins 0.000 claims 3
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 3
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 3
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 3
- 101710151321 Melanostatin Proteins 0.000 claims 3
- 102400000064 Neuropeptide Y Human genes 0.000 claims 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 3
- 102000023984 PPAR alpha Human genes 0.000 claims 3
- 108010016731 PPAR gamma Proteins 0.000 claims 3
- 108010044210 PPAR-beta Proteins 0.000 claims 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 3
- 229940100389 Sulfonylurea Drugs 0.000 claims 3
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000009102 absorption Effects 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 3
- 239000000048 adrenergic agonist Substances 0.000 claims 3
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 3
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 3
- 239000003524 antilipemic agent Substances 0.000 claims 3
- 229940127218 antiplatelet drug Drugs 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 229940097320 beta blocking agent Drugs 0.000 claims 3
- 229960000516 bezafibrate Drugs 0.000 claims 3
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 claims 3
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 3
- 229960001214 clofibrate Drugs 0.000 claims 3
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 3
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims 3
- 229960004597 dexfenfluramine Drugs 0.000 claims 3
- 229960004890 diethylpropion Drugs 0.000 claims 3
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims 3
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 3
- 229960003638 dopamine Drugs 0.000 claims 3
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 claims 3
- 230000003028 elevating effect Effects 0.000 claims 3
- 230000029142 excretion Effects 0.000 claims 3
- 229960001582 fenfluramine Drugs 0.000 claims 3
- 229960002297 fenofibrate Drugs 0.000 claims 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 3
- 229940125753 fibrate Drugs 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 229960003627 gemfibrozil Drugs 0.000 claims 3
- 239000003382 histamine H3 receptor agonist Substances 0.000 claims 3
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 3
- 239000000411 inducer Substances 0.000 claims 3
- 229960000299 mazindol Drugs 0.000 claims 3
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 3
- 235000005152 nicotinamide Nutrition 0.000 claims 3
- 239000011570 nicotinamide Substances 0.000 claims 3
- 229960003966 nicotinamide Drugs 0.000 claims 3
- 229960003512 nicotinic acid Drugs 0.000 claims 3
- 235000001968 nicotinic acid Nutrition 0.000 claims 3
- 239000011664 nicotinic acid Substances 0.000 claims 3
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims 3
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 3
- 229960003562 phentermine Drugs 0.000 claims 3
- 229960000395 phenylpropanolamine Drugs 0.000 claims 3
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 3
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 3
- 229960003611 pramlintide Drugs 0.000 claims 3
- 108010029667 pramlintide Proteins 0.000 claims 3
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 claims 3
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims 3
- 229960003912 probucol Drugs 0.000 claims 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 3
- 229960004622 raloxifene Drugs 0.000 claims 3
- 230000009103 reabsorption Effects 0.000 claims 3
- 239000002464 receptor antagonist Substances 0.000 claims 3
- 229940044551 receptor antagonist Drugs 0.000 claims 3
- 230000028327 secretion Effects 0.000 claims 3
- 229960004425 sibutramine Drugs 0.000 claims 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 3
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 3
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 3
- 229960003732 tyramine Drugs 0.000 claims 3
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 claims 3
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 2
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 claims 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- 102100025841 Cholecystokinin Human genes 0.000 claims 2
- 101800001982 Cholecystokinin Proteins 0.000 claims 2
- 101800000414 Corticotropin Proteins 0.000 claims 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 2
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 2
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 2
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 claims 2
- 101710181187 Liver carboxylesterase 1 Proteins 0.000 claims 2
- 229940123464 Thiazolidinedione Drugs 0.000 claims 2
- 229930003268 Vitamin C Natural products 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 2
- 230000003178 anti-diabetic effect Effects 0.000 claims 2
- 239000003529 anticholesteremic agent Substances 0.000 claims 2
- 239000003472 antidiabetic agent Substances 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 229940107137 cholecystokinin Drugs 0.000 claims 2
- 229960000258 corticotropin Drugs 0.000 claims 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims 2
- 239000002319 fibrinogen receptor antagonist Substances 0.000 claims 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 2
- 229940039781 leptin Drugs 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 102000006255 nuclear receptors Human genes 0.000 claims 2
- 229960002847 prasterone Drugs 0.000 claims 2
- 108010070701 procolipase Proteins 0.000 claims 2
- 239000003488 releasing hormone Substances 0.000 claims 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims 2
- 235000019154 vitamin C Nutrition 0.000 claims 2
- 239000011718 vitamin C Substances 0.000 claims 2
- 235000019165 vitamin E Nutrition 0.000 claims 2
- 229940046009 vitamin E Drugs 0.000 claims 2
- 239000011709 vitamin E Substances 0.000 claims 2
- OCVLSHAVSIYKLI-UHFFFAOYSA-N 3h-1,3-thiazole-2-thione Chemical compound SC1=NC=CS1 OCVLSHAVSIYKLI-UHFFFAOYSA-N 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- NQQMUAALTMRXKD-WOARFCOISA-N C1=CC(NC(=O)C)=CC=C1\N=C(/S\1)N(CC=2OC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 Chemical compound C1=CC(NC(=O)C)=CC=C1\N=C(/S\1)N(CC=2OC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 NQQMUAALTMRXKD-WOARFCOISA-N 0.000 claims 1
- GCVLCLFIEOVLMG-JTUXUYRKSA-N CC(=O)C1=CC=CC(\N=C/2N(C(=O)C(=C/N3C4=CC=CC=C4CC3)/S\2)CC=2OC=CC=2)=C1 Chemical compound CC(=O)C1=CC=CC(\N=C/2N(C(=O)C(=C/N3C4=CC=CC=C4CC3)/S\2)CC=2OC=CC=2)=C1 GCVLCLFIEOVLMG-JTUXUYRKSA-N 0.000 claims 1
- DXNSGASFGISSOY-QMIAEUBZSA-N CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CC1=CC=CC=C1 Chemical compound CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CC1=CC=CC=C1 DXNSGASFGISSOY-QMIAEUBZSA-N 0.000 claims 1
- HKFQHSDEEUNRTI-LKNIRPGHSA-N CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 Chemical compound CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 HKFQHSDEEUNRTI-LKNIRPGHSA-N 0.000 claims 1
- FRRBVAOXYDQYKI-ICDTUWNZSA-N CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/NC1=CC=C(OC)C=C1 Chemical compound CCNC1=CC=C(C#N)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/NC1=CC=C(OC)C=C1 FRRBVAOXYDQYKI-ICDTUWNZSA-N 0.000 claims 1
- ZQWBBJKQQQLRBO-YWNZOVFCSA-N CCNC1=CC=C(C#N)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(=C/N(C)C)/S\1 Chemical compound CCNC1=CC=C(C#N)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(=C/N(C)C)/S\1 ZQWBBJKQQQLRBO-YWNZOVFCSA-N 0.000 claims 1
- KYXHFHACYVKHAB-YMURDISESA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/C1=CC=CC=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/C1=CC=CC=C1 KYXHFHACYVKHAB-YMURDISESA-N 0.000 claims 1
- PZCIROBDGVLEIL-KHHYFDFNSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/C1=CC=CO1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/C1=CC=CO1 PZCIROBDGVLEIL-KHHYFDFNSA-N 0.000 claims 1
- XABCMNNTHFJDCF-GVZJHPDTSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=C(OCCOC)C=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=C(OCCOC)C=C1 XABCMNNTHFJDCF-GVZJHPDTSA-N 0.000 claims 1
- PDXNFKUZVGOMRC-BOTKPODPSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=CC(OC)=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=CC(OC)=C1 PDXNFKUZVGOMRC-BOTKPODPSA-N 0.000 claims 1
- VZGIJCXVUUINRV-GWVUPHRNSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=CC=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)C1=CC=CC=C1 VZGIJCXVUUINRV-GWVUPHRNSA-N 0.000 claims 1
- BZXKLXUWHZDDTA-DINUBHSRSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CC1=CC=CC=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CC1=CC=CC=C1 BZXKLXUWHZDDTA-DINUBHSRSA-N 0.000 claims 1
- GMUCPXKPCHHGMW-ATKAZLLPSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CCC1=CC=CC=C1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N(C)CCC1=CC=CC=C1 GMUCPXKPCHHGMW-ATKAZLLPSA-N 0.000 claims 1
- HLSDYWFUKOZJTE-BOTKPODPSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1C2=CC=CC=C2CC1 HLSDYWFUKOZJTE-BOTKPODPSA-N 0.000 claims 1
- ZWQHCOQRXKFJGB-ULVCWHGLSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1CCN(C)CC1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C(/S\1)N(CC=2C=CC=CC=2)C(=O)C/1=C/N1CCN(C)CC1 ZWQHCOQRXKFJGB-ULVCWHGLSA-N 0.000 claims 1
- QRMFPGOYLMAMMW-YVADOFBFSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(=C/N(C)C)/S\1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(=C/N(C)C)/S\1 QRMFPGOYLMAMMW-YVADOFBFSA-N 0.000 claims 1
- FTTCNMOCBHYESC-HYOGKJQXSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CC(=O)C=2C=CC=CC=2)S\1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CC(=O)C=2C=CC=CC=2)S\1 FTTCNMOCBHYESC-HYOGKJQXSA-N 0.000 claims 1
- UEKDOPPDCYNGHM-OHYPFYFLSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CC=2C=CC=CC=2)S\1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CC=2C=CC=CC=2)S\1 UEKDOPPDCYNGHM-OHYPFYFLSA-N 0.000 claims 1
- UYOKDJNIHORDNT-HYOGKJQXSA-N CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CCC=2C=CC=CC=2)S\1 Chemical compound CCNC1=CC=C(C(C)=O)C=C1\N=C/1N(CC=2C=CC=CC=2)C(=O)C(CCC=2C=CC=CC=2)S\1 UYOKDJNIHORDNT-HYOGKJQXSA-N 0.000 claims 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims 1
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 claims 1
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 claims 1
- 229940122206 Farnesoid X receptor antagonist Drugs 0.000 claims 1
- 108010012088 Fibrinogen Receptors Proteins 0.000 claims 1
- 229940086609 Lipase inhibitor Drugs 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 210000000941 bile Anatomy 0.000 claims 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims 1
- 239000005516 coenzyme A Substances 0.000 claims 1
- 229940093530 coenzyme a Drugs 0.000 claims 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 claims 1
- 239000004062 cytokinin Substances 0.000 claims 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 20
- 108020003175 receptors Proteins 0.000 abstract description 20
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 47
- 102000004164 orphan nuclear receptors Human genes 0.000 description 21
- 108090000629 orphan nuclear receptors Proteins 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 13
- 108010038912 Retinoid X Receptors Proteins 0.000 description 11
- 102000034527 Retinoid X Receptors Human genes 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- XHNJAEUCAPAPFV-UHFFFAOYSA-N 3,4-dihydropyrrol-2-imine Chemical compound N=1C(CCC=1)=N XHNJAEUCAPAPFV-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 6
- HYMJHROUVPWYNQ-UHFFFAOYSA-N 2-amino-1,3-thiazol-4-one Chemical compound NC1=NC(=O)CS1 HYMJHROUVPWYNQ-UHFFFAOYSA-N 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 150000001718 carbodiimides Chemical class 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- OLAXGXSXHZEQFM-UHFFFAOYSA-N 5-(aminomethylidene)-3,4-dihydropyrrol-2-amine Chemical compound NC=C1CCC(=N)N1 OLAXGXSXHZEQFM-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- 108091027981 Response element Proteins 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 229910000397 disodium phosphate Inorganic materials 0.000 description 4
- 235000019800 disodium phosphate Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 239000000833 heterodimer Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229940036555 thyroid hormone Drugs 0.000 description 4
- 239000005495 thyroid hormone Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000001883 cholelithiasis Diseases 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002084 enol ethers Chemical class 0.000 description 3
- 208000001130 gallstones Diseases 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 101710128505 Bile acid receptor Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- UPEZCKBFRMILAV-JNEQICEOSA-N Ecdysone Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@H]([C@@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 UPEZCKBFRMILAV-JNEQICEOSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 102000016978 Orphan receptors Human genes 0.000 description 2
- 108070000031 Orphan receptors Proteins 0.000 description 2
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- UPEZCKBFRMILAV-UHFFFAOYSA-N alpha-Ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C(O)CCC(C)(C)O)C)CCC33O)C)C3=CC(=O)C21 UPEZCKBFRMILAV-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960000510 ammonia Drugs 0.000 description 2
- 102000001307 androgen receptors Human genes 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229910052788 barium Inorganic materials 0.000 description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
- 230000037365 barrier function of the epidermis Effects 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229940043237 diethanolamine Drugs 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- UPEZCKBFRMILAV-JMZLNJERSA-N ecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@H]([C@H](O)CCC(C)(C)O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 UPEZCKBFRMILAV-JMZLNJERSA-N 0.000 description 2
- 238000000119 electrospray ionisation mass spectrum Methods 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 229940086735 succinate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Chemical class 0.000 description 2
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- FBZVZUSVGKOWHG-UHFFFAOYSA-N 1,1-dimethoxy-n,n-dimethylethanamine Chemical compound COC(C)(OC)N(C)C FBZVZUSVGKOWHG-UHFFFAOYSA-N 0.000 description 1
- JXPFJBJQNHEHKD-UHFFFAOYSA-N 2-amino-5-(aminomethylidene)-1,3-thiazol-4-one Chemical compound NC=C1SC(=N)NC1=O JXPFJBJQNHEHKD-UHFFFAOYSA-N 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- NJBMZYSKLWQXLJ-UHFFFAOYSA-N 3,4-dihydro-2h-pyrrol-5-amine Chemical compound NC1=NCCC1 NJBMZYSKLWQXLJ-UHFFFAOYSA-N 0.000 description 1
- FDKVVPGVZUSTGF-UHFFFAOYSA-N 3-[[3-benzyl-5-[(4-methoxy-n-methylanilino)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-4-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(C#N)C=C1N=C(S1)N(CC=2C=CC=CC=2)C(=O)C1=CN(C)C1=CC=C(OC)C=C1 FDKVVPGVZUSTGF-UHFFFAOYSA-N 0.000 description 1
- ASNHGEVAWNWCRQ-UHFFFAOYSA-N 4-(hydroxymethyl)oxolane-2,3,4-triol Chemical compound OCC1(O)COC(O)C1O ASNHGEVAWNWCRQ-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 102100038637 Cytochrome P450 7A1 Human genes 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000957672 Homo sapiens Cytochrome P450 7A1 Proteins 0.000 description 1
- 101000640876 Homo sapiens Retinoic acid receptor RXR-beta Proteins 0.000 description 1
- 101000640882 Homo sapiens Retinoic acid receptor RXR-gamma Proteins 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 1
- 102100021316 Mineralocorticoid receptor Human genes 0.000 description 1
- 208000034493 Mucous membrane disease Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102100034253 Retinoic acid receptor RXR-beta Human genes 0.000 description 1
- 102100034262 Retinoic acid receptor RXR-gamma Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005125 aryl alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 150000007981 azolines Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 150000002031 dolichols Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108091005640 farnesylated proteins Proteins 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 150000002373 hemiacetals Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 102000027419 nuclear receptor subfamilies Human genes 0.000 description 1
- 108091008607 nuclear receptor subfamilies Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 238000001403 relative X-ray reflectometry Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CRDYSYOERSZTHZ-UHFFFAOYSA-M selenocyanate Chemical compound [Se-]C#N CRDYSYOERSZTHZ-UHFFFAOYSA-M 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
- 125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60023904P | 2004-08-10 | 2004-08-10 | |
| PCT/US2005/028357 WO2006020680A2 (en) | 2004-08-10 | 2005-08-09 | Heterocyclic compounds as pharmaceutical agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008509912A true JP2008509912A (ja) | 2008-04-03 |
| JP2008509912A5 JP2008509912A5 (https=) | 2008-09-25 |
Family
ID=35908114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007525749A Pending JP2008509912A (ja) | 2004-08-10 | 2005-08-09 | 医薬品としての複素環化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7902237B2 (https=) |
| EP (1) | EP1776112A4 (https=) |
| JP (1) | JP2008509912A (https=) |
| CN (1) | CN101010078A (https=) |
| AU (1) | AU2005272916A1 (https=) |
| BR (1) | BRPI0514269A (https=) |
| CA (1) | CA2574279A1 (https=) |
| MX (1) | MX2007001539A (https=) |
| WO (1) | WO2006020680A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018184443A (ja) * | 2012-06-19 | 2018-11-22 | インターセプト ファーマシューティカルズ， インコーポレイテッド | オベチコール酸の調製、使用および固体形態 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090156644A1 (en) * | 2005-07-21 | 2009-06-18 | Jacob Westman | Use of thiazole derivatives and analogues in the treatment of cancer |
| DE102007003524A1 (de) * | 2007-01-19 | 2008-09-04 | MEDICE Arzneimittel Pütter GmbH & Co. KG | Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose |
| WO2008090356A1 (en) * | 2007-01-25 | 2008-07-31 | Betagenon Ab | Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity |
| CN101274918A (zh) * | 2007-03-30 | 2008-10-01 | 中国科学院上海药物研究所 | 一类取代五元杂环化合物,其制备方法和医学用途 |
| WO2010086613A1 (en) | 2009-01-30 | 2010-08-05 | Betagenon Ab | Compounds useful as inhibitors as ampk |
| WO2012106581A1 (en) * | 2011-02-03 | 2012-08-09 | The University Of Chicago | Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction |
| JP6556129B2 (ja) | 2013-08-01 | 2019-08-07 | アメリカ合衆国 | ファルネソイドｘ受容体の阻害剤及び医薬としての使用 |
| SI3043865T1 (sl) | 2013-09-11 | 2021-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B |
| EP2952188A1 (en) * | 2014-06-03 | 2015-12-09 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
| EP3148541B1 (en) | 2014-05-28 | 2020-09-02 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
| EP3715348A1 (en) | 2015-03-26 | 2020-09-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| TW201741307A (zh) * | 2016-02-22 | 2017-12-01 | 艾洛斯生物製藥公司 | Ｆｘｒ調節劑及其使用方法 |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| JP2020530477A (ja) * | 2017-08-10 | 2020-10-22 | ザ テキサス エーアンドエム ユニヴァーシティ システム | Ｎｒ４ａ１リガンド、医薬組成物、及び関連する使用方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE523919A (https=) * | 1952-10-31 | |||
| US2719162A (en) * | 1954-03-29 | 1955-09-27 | Eastman Kodak Co | 5-(3-hydroxybenzylidene)-3-phenyl-2-phenylimino-4-thiazolidone and process |
| US3097100A (en) * | 1960-01-25 | 1963-07-09 | Eastman Kodak Co | Thiazolidones as light stabilizers for plastic compositions |
| BE608790A (fr) | 1960-10-08 | 1962-04-03 | Kalle Ag | Matériel photosensible. |
| US3314794A (en) | 1964-05-13 | 1967-04-18 | Eastman Kodak Co | Ultraviolet absorbers |
| FR1604530A (https=) * | 1967-06-06 | 1971-11-29 | ||
| US5198454A (en) * | 1991-12-03 | 1993-03-30 | Texas A&M University System | Use of OB-104 to treat ocular inflammation |
| JPH06128234A (ja) | 1992-10-19 | 1994-05-10 | Fuji Photo Film Co Ltd | 不斉炭素原子を有する化合物およびそれからなる非線形光学材料 |
| JP3871354B2 (ja) * | 1994-07-29 | 2007-01-24 | 株式会社フジモト・コーポレーション | 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体 |
| US6353006B1 (en) * | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
| ES2367539T3 (es) * | 2001-12-21 | 2011-11-04 | X-Ceptor Therapeutics, Inc. | Moduladores heterocíclicos de receptores nucleares. |
-
2005
- 2005-08-09 MX MX2007001539A patent/MX2007001539A/es not_active Application Discontinuation
- 2005-08-09 EP EP05786284A patent/EP1776112A4/en not_active Withdrawn
- 2005-08-09 BR BRPI0514269-5A patent/BRPI0514269A/pt not_active IP Right Cessation
- 2005-08-09 CA CA002574279A patent/CA2574279A1/en not_active Abandoned
- 2005-08-09 CN CNA2005800272537A patent/CN101010078A/zh active Pending
- 2005-08-09 JP JP2007525749A patent/JP2008509912A/ja active Pending
- 2005-08-09 US US11/573,614 patent/US7902237B2/en not_active Expired - Fee Related
- 2005-08-09 AU AU2005272916A patent/AU2005272916A1/en not_active Abandoned
- 2005-08-09 WO PCT/US2005/028357 patent/WO2006020680A2/en not_active Ceased
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018184443A (ja) * | 2012-06-19 | 2018-11-22 | インターセプト ファーマシューティカルズ， インコーポレイテッド | オベチコール酸の調製、使用および固体形態 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1776112A4 (en) | 2009-11-25 |
| WO2006020680A2 (en) | 2006-02-23 |
| BRPI0514269A (pt) | 2008-06-10 |
| US7902237B2 (en) | 2011-03-08 |
| US20080132519A1 (en) | 2008-06-05 |
| EP1776112A2 (en) | 2007-04-25 |
| CA2574279A1 (en) | 2006-02-23 |
| MX2007001539A (es) | 2007-04-23 |
| CN101010078A (zh) | 2007-08-01 |
| AU2005272916A1 (en) | 2006-02-23 |
| WO2006020680A3 (en) | 2006-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5420908B2 (ja) | 医薬的薬剤としてのアゼピノインドール誘導体 | |
| JP4679517B2 (ja) | 薬剤としてのアゼピン誘導体 | |
| US7115640B2 (en) | Heterocyclic modulators of nuclear receptors | |
| KR101270072B1 (ko) | 약제로서의 아제피노인돌 유도체 | |
| US7910770B2 (en) | Fc receptor modulating compounds and compositions | |
| JP2008509912A (ja) | 医薬品としての複素環化合物 | |
| TWI304066B (en) | Indole compounds | |
| RU2720488C2 (ru) | Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия | |
| JP2012503654A (ja) | １，２，３，６−テトラヒドロアゼピノ［４，５−ｂ］インドール−５−カルボキシレート核内受容体阻害剤 | |
| ES2331299T3 (es) | Compuestos de lactama y su uso medico. | |
| WO2010006496A1 (zh) | 用作雌激素相关受体调节剂的化合物及其应用 | |
| EP3715348A1 (en) | Fused bicyclic compounds for the treatment of disease | |
| JP2002053557A (ja) | アポリポ蛋白ａ−ｉ産生促進薬 | |
| JP3348505B2 (ja) | ベンゾオキサジン−３−オン化合物 | |
| Bennamane et al. | N-Substituted [phenyl-pyrazolo]-oxazin-2-thiones as COX-LOX inhibitors: influence of the replacement of the oxo-group with thioxo-group on the COX inhibition activity of N-substituted pyrazolo-oxazin-2-ones | |
| US4902688A (en) | 4-(3-Coumarinyl)-thiazole-derivatives with anti-allergic, anti-anaphylactic and anti-arthritic activity and compositions containing them | |
| CN101374842A (zh) | 作为药物剂的氮杂卓并吲哚衍生物 | |
| HK40049146A (en) | Fused bicyclic compounds for the treatment of disease | |
| AU2014297912A1 (en) | Novel indazole compounds and a process for the preparation thereof | |
| HK1166982A (en) | Azepinoindole derivatives as pharmaceutical agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080808 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080808 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110601 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110613 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111114 |